[go: up one dir, main page]

BG102526A - Твърди дозирани форми, съдържащи флурбипрофен - Google Patents

Твърди дозирани форми, съдържащи флурбипрофен

Info

Publication number
BG102526A
BG102526A BG102526A BG10252698A BG102526A BG 102526 A BG102526 A BG 102526A BG 102526 A BG102526 A BG 102526A BG 10252698 A BG10252698 A BG 10252698A BG 102526 A BG102526 A BG 102526A
Authority
BG
Bulgaria
Prior art keywords
dosage forms
solid dosage
ferbibroprophen
forms containing
tonsillitis
Prior art date
Application number
BG102526A
Other languages
English (en)
Other versions
BG64166B1 (bg
Inventor
David Barrett
Carl Smith
David THURGOOD
Original Assignee
The Boots Company Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Boots Company Plc filed Critical The Boots Company Plc
Publication of BG102526A publication Critical patent/BG102526A/bg
Publication of BG64166B1 publication Critical patent/BG64166B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Твърдите дозирани форми за дъвчене или смукане или като спрей съдържат терапевтичноефективно количество флурбипрофен, който се освобождава в устната кухина и достига повърхността на тонзилита. Приложими са при лечение на тонзилити.
BG102526A 1995-11-22 1998-06-09 Твърди дозирани форми, съдържащи флурбипрофен BG64166B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9523833.3A GB9523833D0 (en) 1995-11-22 1995-11-22 Medical treatment
PCT/EP1996/005208 WO1997018802A1 (en) 1995-11-22 1996-11-21 Pharmaceutical compositions comprising flurbiprofen

Publications (2)

Publication Number Publication Date
BG102526A true BG102526A (bg) 1999-02-26
BG64166B1 BG64166B1 (bg) 2004-03-31

Family

ID=10784245

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102526A BG64166B1 (bg) 1995-11-22 1998-06-09 Твърди дозирани форми, съдържащи флурбипрофен

Country Status (21)

Country Link
US (2) US5889057A (bg)
EP (1) EP0862424B1 (bg)
CN (1) CN1148177C (bg)
AT (1) ATE252382T1 (bg)
AU (1) AU707749B2 (bg)
BG (1) BG64166B1 (bg)
CA (1) CA2238271C (bg)
CZ (1) CZ289643B6 (bg)
DE (1) DE69630460T2 (bg)
DK (1) DK0862424T3 (bg)
ES (1) ES2208768T3 (bg)
GB (1) GB9523833D0 (bg)
HU (1) HU225235B1 (bg)
IL (1) IL124568A0 (bg)
NO (1) NO317287B1 (bg)
NZ (1) NZ322933A (bg)
PT (1) PT862424E (bg)
RU (1) RU2203655C2 (bg)
SK (1) SK284092B6 (bg)
UA (1) UA46807C2 (bg)
WO (1) WO1997018802A1 (bg)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
WO1998052540A1 (en) * 1997-05-22 1998-11-26 The Boots Company Plc Pharmaceutical compositions
AU7916798A (en) * 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
GB9710521D0 (en) * 1997-05-22 1997-07-16 Boots Co Plc Process
WO2000069470A2 (en) * 1999-05-17 2000-11-23 Aesgen, Inc. Improved cellular uptake of bioactive agents
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
AR037356A1 (es) * 2001-11-13 2004-11-03 Pharmacia Corp Forma de dosificacion oral de una prodroga de sulfonamida
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
AU2003257963B2 (en) * 2002-08-01 2009-08-13 Board Of Trustees Of The University Of Arkansas Improved treatment of cancer with glutamine
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US20040265359A1 (en) * 2003-04-17 2004-12-30 Sacks Gordon S. Oral delivery formulations of L-glutamine
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
KR20070004036A (ko) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 벽, 옹벽 및 그 외 유사한 것을 위한 베니어
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
GB2423710A (en) 2005-03-01 2006-09-06 Boots Healthcare Int Ltd Lozenge production process
BRPI0613611A2 (pt) * 2005-07-22 2011-01-18 Myriad Genetics Inc formulações de alta concentração de fármaco e formas de dosagens
BRPI0618273A2 (pt) * 2005-11-02 2011-08-23 Teikoku Pharma Usa Inc formulações de dosagem oral de ibuprofeno organolepticamente aceitáveis, métodos de produção e uso das mesmas
US7282224B1 (en) * 2006-06-09 2007-10-16 Guthy-Renker Corporation Pain relief composition
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
US7754234B2 (en) * 2006-07-12 2010-07-13 Jones Thomas L Composition and method of treating a sore throat
US20080107747A1 (en) * 2006-10-23 2008-05-08 Roederer Joy E Pain relief composition
WO2009014960A1 (en) * 2007-07-23 2009-01-29 Teikoku Pharma Usa, Inc. Organoleptically acceptable indole serotonin receptor agonist oral dosage formulations and methods of using the same
NZ596963A (en) 2009-05-19 2014-01-31 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
IT1397132B1 (it) 2009-12-01 2013-01-04 Alfa Wassermann Spa Composizioni comprendenti antiinfiammatori non steroidei.
DK3326615T3 (da) * 2010-11-15 2020-03-09 Neuroderm Ltd Kontinuerlig indgivelse af l-dopa-, dopa- decarboxylase-inhibitorer, catechol-o-methyltransferaseinhibitorer og sammensætninger til samme
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
PL2854764T3 (pl) 2012-06-05 2019-07-31 Neuroderm Ltd Kompozycje zawierające apomorfinę i kwasy organiczne oraz ich zastosowania
GB201216893D0 (en) 2012-09-21 2012-11-07 Aesica Pharmaceuticals Ltd Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen
EP3116475B1 (en) 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN110812331A (zh) * 2018-08-10 2020-02-21 北京普德康利医药科技发展有限公司 一种氟比洛芬咽部滞留颗粒
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
CN115536525B (zh) * 2022-09-23 2024-02-23 南京知和医药科技有限公司 一种s-（+）-氟比洛芬盐及其制备方法、药物组合物和用途
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1091403A (en) * 1964-01-24 1967-11-15 Boots Pure Drug Co Ltd Therapeutically active phenylalkane derivatives
CA1062721A (en) * 1975-12-15 1979-09-18 Anthony A. Sinkula Propionic acid derivatives
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPH0647532B2 (ja) * 1983-08-31 1994-06-22 ジ アツプジヨン カンパニ− 歯槽骨吸収の治療
EP0228223A3 (en) * 1985-12-16 1987-09-09 Cilag AG Non-irritating suprofen solution
EP0321505A1 (en) * 1986-10-22 1989-06-28 The Upjohn Company Treatment of gingivitis with ibuprofen or flurbiprofen
JPS63156715A (ja) * 1986-12-19 1988-06-29 Teisan Seiyaku Kk 即効性の徐放化製剤
JP2540581B2 (ja) * 1988-02-04 1996-10-02 三省製薬株式会社 外用剤
US4931473A (en) * 1989-02-15 1990-06-05 Richardson-Vicks Inc. Anesthetic oral compositions
US5190981A (en) * 1989-08-17 1993-03-02 Sepracor Inc. Formulation containing S(+) enantiomer of flurbiprofen or ketoprofen and method of use for oral administration for prevention and treatment of bone loss associated with periodontal disease
ES2067754T5 (es) * 1989-08-17 1998-10-01 Sepracor Inc Composicion bucal que contiene s(+) flurbiprofeno o ketoprofeno.
JP2738092B2 (ja) * 1989-11-17 1998-04-08 ライオン株式会社 口腔用組成物
GB8928196D0 (en) * 1989-12-13 1990-02-14 Merrell Dow Pharmaceuticals Li Pharmaceutical lozenges
JPH0426618A (ja) * 1990-05-21 1992-01-29 Japan Tobacco Inc トローチ剤
IT1243342B (it) * 1990-07-13 1994-06-10 Farcon Ag Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
EP0627915B1 (en) * 1992-12-04 1999-10-13 Mayor Pharmaceuticals Laboratories,Inc. Sprayable analgesic composition and method of use
WO1994014476A1 (en) * 1992-12-21 1994-07-07 The Procter & Gamble Company Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
HUT76798A (en) * 1994-09-02 1997-11-28 Univ Virginia Commonwealth Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer
US5567733B1 (en) * 1995-04-27 1999-08-24 Jon G Dishler Irritation relief using nonsteroidal anti-inflammatory compounds
EP0837862A1 (en) * 1995-07-05 1998-04-29 The Procter & Gamble Company Warming compounds
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
AU2190697A (en) * 1996-04-12 1997-11-07 Flemington Pharmaceutical Corporation Buccal polar spray or capsule

Also Published As

Publication number Publication date
DE69630460D1 (de) 2003-11-27
BG64166B1 (bg) 2004-03-31
ATE252382T1 (de) 2003-11-15
WO1997018802A1 (en) 1997-05-29
DK0862424T3 (da) 2003-12-29
EP0862424A1 (en) 1998-09-09
HUP0000180A3 (en) 2001-10-29
NZ322933A (en) 2000-02-28
DE69630460T2 (de) 2004-08-19
HU225235B1 (en) 2006-08-28
US5889057A (en) 1999-03-30
AU707749B2 (en) 1999-07-22
NO982294L (no) 1998-07-20
UA46807C2 (uk) 2002-06-17
US6166083A (en) 2000-12-26
ES2208768T3 (es) 2004-06-16
NO317287B1 (no) 2004-10-04
CZ289643B6 (cs) 2002-03-13
GB9523833D0 (en) 1996-01-24
AU2611997A (en) 1997-06-11
CZ156598A3 (cs) 1998-08-12
EP0862424B1 (en) 2003-10-22
RU2203655C2 (ru) 2003-05-10
CN1207677A (zh) 1999-02-10
SK284092B6 (sk) 2004-09-08
CA2238271C (en) 2008-08-12
NO982294D0 (no) 1998-05-20
CN1148177C (zh) 2004-05-05
SK66598A3 (en) 1998-12-02
PT862424E (pt) 2004-02-27
HUP0000180A2 (hu) 2000-08-28
CA2238271A1 (en) 1997-05-29
IL124568A0 (en) 1998-12-06

Similar Documents

Publication Publication Date Title
BG102526A (bg) Твърди дозирани форми, съдържащи флурбипрофен
AU590403B2 (en) Pharmaceutical composition for the treatment of periodontal diseases
EE04111B1 (et) Raku adhesiooni inhibiitorid, nende kasutamine janeid sisaldavad farmatseutilised kompositsioonid
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
AU2001249329A1 (en) Lipoxin analogs and methods for the treatment of periodontal disease
IS4360A (is) Lyfjablanda í skammtaformi til munninntöku
ATE284695T1 (de) Oral anzuwendende arzneizusammensetzung enthaltend 2-methyl-thienobenzodiazepin
HUP0300836A3 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
NO992944D0 (no) Virkestoffbµrer for avgivelse av apomorfin i munnhulen
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
FR2618331B1 (fr) Compositions pharmaceutiques utiles pour le traitement de l'uremie
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69622461D1 (de) Oberflächenbehandlungszusammensetzung
CA2279184A1 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
NO961045D0 (no) Plasterpreparater for behandling av planter
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
AU3709289A (en) Strontium salt
AU4434389A (en) Aqueous oral pharmaceutical preparation of diclofenac
NO982562D0 (no) Sammensetning for behandling av smerte
DE69119588D1 (de) Verwendung von ketorolac zur behandlung von periodontitis
DK0934342T3 (da) Præparat indeholdende chitosan
NO167381C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv (e)-2-(p-fluorfenethyl)-3-fluorallylamin.
NO924767L (no) Anordning for bedring av miljö i munnhulen ved tannbehandling
KR970000226A (ko) S-이부프로펜의 경구용 제형
IL105714A0 (en) Oral dosage forms of risedronate